| Dr Patrick W Daly, MD | |
|
3629 Fairmount St, Dallas, TX 75219-4710 | |
| (214) 526-3566 | |
| (214) 522-8619 |
| Full Name | Dr Patrick W Daly |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 41 Years |
| Location | 3629 Fairmount St, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063480853 | NPI | - | NPPES |
| 752317753 | Other | TX | TAXID |
| 0354961-01 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | G4949 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Express Nursing | Odessa, TX | Home health agency |
| Big Bend Regional Medical Center | Alpine, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Preventative Care Health Services Inc | 5193823045 | 7 |
News Archive
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Cr-teil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.
A study published in the May/June issue of Health Affairs reports on the first randomized trial providing a scientifically valid look at what one might expect from chronic disease management programs that serve low-income individuals. The study result provides good news for state Medicaid leaders struggling to meet the needs of individuals with chronic conditions and also suggests that some disease management efforts, even among relatively low-risk patients, may be an effective strategy.
In 2002-03, over four million Australians were admitted to our public hospitals, over half a million people had elective surgery and nearly four million people went to an emergency department for treatment.
› Verified 1 days ago
| Entity Name | Medhealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912957200 PECOS PAC ID: 9931001567 Enrollment ID: O20040123000832 |
News Archive
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Cr-teil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.
A study published in the May/June issue of Health Affairs reports on the first randomized trial providing a scientifically valid look at what one might expect from chronic disease management programs that serve low-income individuals. The study result provides good news for state Medicaid leaders struggling to meet the needs of individuals with chronic conditions and also suggests that some disease management efforts, even among relatively low-risk patients, may be an effective strategy.
In 2002-03, over four million Australians were admitted to our public hospitals, over half a million people had elective surgery and nearly four million people went to an emergency department for treatment.
› Verified 1 days ago
| Entity Name | Preventative Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013196625 PECOS PAC ID: 5193823045 Enrollment ID: O20091110000495 |
News Archive
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Cr-teil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.
A study published in the May/June issue of Health Affairs reports on the first randomized trial providing a scientifically valid look at what one might expect from chronic disease management programs that serve low-income individuals. The study result provides good news for state Medicaid leaders struggling to meet the needs of individuals with chronic conditions and also suggests that some disease management efforts, even among relatively low-risk patients, may be an effective strategy.
In 2002-03, over four million Australians were admitted to our public hospitals, over half a million people had elective surgery and nearly four million people went to an emergency department for treatment.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick W Daly, MD 3629 Fairmount St, Dallas, TX 75219-4710 Ph: (214) 526-3566 | Dr Patrick W Daly, MD 3629 Fairmount St, Dallas, TX 75219-4710 Ph: (214) 526-3566 |
News Archive
Chronix Biomedical today reported a summary of data supporting the utility of its serum DNA blood tests for the early and accurate detection of breast cancer and prostate cancer. The unique testing algorithms developed by Chronix detected and correctly identified DNA fragments in the blood from dying (apoptotic) cancer cells with 92% sensitivity and 100% specificity in both prostate cancer and breast cancer.
Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).
The clinical trials aim to repair bones using adult stem cells combined with biomaterials. It will be conducted in France in the Cr-teil University Hospital Centre and the Regional University Hospital Centre in Tours, in collaboration with the French Blood Establishment.
A study published in the May/June issue of Health Affairs reports on the first randomized trial providing a scientifically valid look at what one might expect from chronic disease management programs that serve low-income individuals. The study result provides good news for state Medicaid leaders struggling to meet the needs of individuals with chronic conditions and also suggests that some disease management efforts, even among relatively low-risk patients, may be an effective strategy.
In 2002-03, over four million Australians were admitted to our public hospitals, over half a million people had elective surgery and nearly four million people went to an emergency department for treatment.
› Verified 1 days ago
Uma B.r.k Pakkivenkata, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 215, Dallas, TX 75231 Phone: 214-396-4950 Fax: 877-423-5360 | |
Dr. Ariel Marcelo Modrykamien, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 Gaston Ave, Wadley Tower, Suite 960, Dallas, TX 75246 Phone: 402-972-6078 | |
Benjamin Seth Martinez, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-3111 Fax: 214-648-5461 | |
Vijaya Mummadi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 9900 N Central Expy Ste 225, Dallas, TX 75231 Phone: 469-646-8880 Fax: 469-646-8884 | |
Dr. Ting-yi Chen, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-645-2800 Fax: 214-645-2808 | |
William Cook Langmade, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1441 N Beckley Ave, Dallas, TX 75203 Phone: 214-947-2306 | |
Dr. Janame J Kottey, MBBS Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 13154 Coit Rd Ste 100, Dallas, TX 75240 Phone: 214-358-2300 Fax: 214-579-6989 |